IMC-001

Phase 2Small molecule

IImmuneOncia Therapeutics Inc.

IMC-001 is one of 30 small molecule programs targeting Locally Advanced. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally AdvancedRecruiting

Subjects With Resectable and Localized Gastric CancerActive, not recruiting

Extranodal NK/T-Cell Lymphoma, Nasal TypeActive, not recruiting

Locally AdvancedPhase 2

Recruiting

Subjects With Resectable and Localized Gastric CancerPhase 2

Active, not recruiting

Extranodal NK/T-Cell Lymphoma, Nasal TypePhase 2

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Locally Advanced

#DrugCompanyPhaseTrials

Eloxatin

Teva

Approved

6 2

Camptosar

Pfizer

Approved

2 3

Adrucil

EElorac, Inc.

Approved

5 4

Taxol

Teva

Phase 3

7 5

Truqap

AstraZeneca

Phase 3

1 6

Paraplatin

AAvyxa

Phase 3

8 7

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

2 8

Keytruda

Merck & Co.

Phase 2

11 9

Immunotherapy

Bristol-Myers Squibb

Phase 3

2 10

Lenvima

Eisai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Extranodal NK/T-Cell Lymphoma, Nasal Type

NCT04414163

Q3 2028

Phase 2Active, not recruiting

Subjects With Resectable and Localized Gastric Cancer

NCT04196465

Q3 2029

Phase 2Recruiting

Locally Advanced

NCT06365840

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

Completed·IImmuneOncia Therapeutics Inc.·Phase 1·NCT03644056·15 enrolled

Locally Advanced1 trial

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

Recruiting·IImmuneOncia Therapeutics Inc.·Phase 2·NCT06365840·30 enrolled

Subjects With Resectable and Localized Gastric Cancer1 trial

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(Neo-Chance Study)

Active, not recruiting·AAsan Medical Center·Phase 2·NCT04196465·48 enrolled

Extranodal NK/T-cell Lymphoma, Nasal Type1 trial

An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting·IImmuneOncia Therapeutics Inc.·Phase 2·NCT04414163·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for IMC-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMC-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMC-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmuneOncia Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IImmuneOncia Therapeutics Inc.

IMC-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2028

Q3 2029

Trials by Indication[1]

Advanced Solid Tumors1 trial

Locally Advanced1 trial

Subjects With Resectable and Localized Gastric Cancer1 trial

Extranodal NK/T-cell Lymphoma, Nasal Type1 trial

References

Drug Info

Quick Facts

Related News